Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2025 06:00 ET | Source: Priothera

Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen

Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing...
November 27, 2023 03:00 ET | Source: Priothera

Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers Mocravimod is being investigated in a global registration-enabling Phase 3...
February 27, 2023 03:00 ET | Source: Priothera

Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant

Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage...